Healthcare Professionals

Resolute Integrity™ DES

Zotarolimus-Eluting Coronary Stent System

DES Technology for Today + Tomorrow

Coronary Stenting in Daily Practice

The Resolute Integrity™ drug-eluting coronary stent simplifies everyday challenges in your increasingly complex clinical practice.

Featuring the unique Continuous Sinusoid Technology of Integrity™ BMS, and a biocompatible polymer specifically designed for DES, Resolute Integrity DES delivers excellent acute performance and powerful clinical performance.

Product Details

A paradigm shift in stent design and manufacturing: Continuous Sinusoid Technology

Continuous Sinusoid Technology
Flexible stent platform for outstanding flexibility and conformability

Continuous Sinusoid Technology

A single strand of cobalt alloy is formed into a sinusoid, wrapped in a helical pattern, and laser fused.

Built to deliver

  • DES technology for today + tomorrow:
    • Unique Continuous Sinusoid Technology defines current performance and enables future innovations 
  • First FDA-approved DES for the treatment of CAD in patients with diabetes2
  • Powerful clinical evidence to address challenging cases:
    • More than 7600 patients studied, including a real-world patient population3 

Incorporates the BioLinx™ biocompatible polymer specifically designed for drug-eluting stents:

  • Rapid endothelial healing4
  • Minimal inflammation4
  • Low risk of stent thrombosis5
  • Controlled drug elution5

BIO-RESORT6 and TRANSFORM OCT7 showed no benefit of bioabsorbable polymer DES over durable BioLinx polymer DES.

Product Specifications

Resolute Integrity DES Product Ordering Information

RESOLUTE All Comers 12-month data. RESOLUTE All Comers evaluated the Resolute™ stent.


Resolute Integrity DES IFU.


Silber S. Five-year follow-up of safety and efficacy of the Resolute zotarolimus-eluting stent: Insights from the Global RESOLUTE Clinical Trial Program in approximately 8000 patients, EuroPCR 2015.


In porcine models. Based on test data on file at Medtronic. May not be indicative of clinical performance.


Yeh et al. 5-year safety and efficacy of resolute zotarolimus-eluting stent. JACC Cardiovascular Interventions. 2017;10:247–254.


Von Birgelen et al. Data presented at TCT 2016. 


Guagliumi et al. Data presented at PCR 2016. Investigator-initiated study not funded by Medtronic.

© 2018 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. ™* Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. For distribution in the USA only.